Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31152409 | 1.00 | CYP3A4 (0.45) | CYP3A4ALDH1A1POLBTDP1HSD17B10 | |
| SCHEMBL4822306 | 0.83 | CYP3A4 (0.48) | CYP3A4ALDH1A1POLBTDP1TRPA1 | |
| SCHEMBL11044958 | 0.80 | CYP3A4 (0.45) | CYP3A4ALDH1A1POLBTDP1TRPA1 | |
| SCHEMBL3412658 | 0.80 | CA2 (0.47) | CYP3A4ALDH1A1POLB | |
| SCHEMBL10411478 | 0.80 | CYP3A4 (0.50) | CYP3A4ALDH1A1POLBTDP1TRPA1 | |
| SCHEMBL8678321 | 0.80 | CYP3A4 (0.45) | CYP3A4ALDH1A1POLBTDP1TRPA1 | |
| SCHEMBL1534409 | 0.78 | CYP3A4 (0.44) | CYP3A4ALDH1A1POLBTDP1TRPA1 | |
| SCHEMBL1340781 | 0.77 | HTR6 (0.48) | CYP3A4ALDH1A1POLBGAA | |
| SCHEMBL12234624 | 0.77 | ALDH1A1 (0.41) | ALDH1A1POLBTDP1HSD17B10TRPV4 | |
| SCHEMBL11289493 | 0.76 | CYP3A4 (0.49) | CYP3A4ALDH1A1TDP1HSD17B10TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0154811-A2 | Coupling agents between mineral fillers and polymers | Plüss-Staufer AG (CH) | 1985-09-18 | — | — | EP | claimed |
| WO-1985003505-A2 | COUPLING AGENT BETWEEN MINERAL FILLERS AND POLYMERS | PLÜSS-STAUFER AG (CH) | 1985-08-15 | — | — | WO | claimed |
| EP-1718623-B1 | COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND VIRAL INFECTIONS | 4SC AG (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-7317030-B2 | Compounds as inhibitors of cell proliferation and viral infections | 4SC AG (DE) | 2008-01-08 | — | — | US | disclosed |
| EP-1718623-A1 | COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND VIRAL INFECTIONS | 4SC AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-6949567-B2 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2005-09-27 | — | — | US | disclosed |
| WO-2005082868-A1 | COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND VIRAL INFECTIONS | 4SC AG (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197368-A1 | Novel compounds as inhibitors of cell proliferation and viral infections | 4SC AG (DE) | 2005-09-08 | — | — | US | disclosed |
| EP-1568696-A1 | Compounds as inhibitors of cell proliferation and viral infections | 4SC AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1395548-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2003-06-26 | — | — | US | disclosed |
| EP-1051655-A4 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | ISTA PHARMACEUTICALS INC (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2002070467-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2002-09-12 | — | — | WO | disclosed |
| EP-1051655-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | Ista Pharmaceuticals, Inc. (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999039238-A1 | METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY | KERATOFORM, INC. (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1997034880-A1 | PROCESS FOR THE PREPARATION OF A β3-AGONIST | MERCK & CO., INC. (US) | 1997-09-25 | — | — | WO | disclosed |
| EP-0154811-A2 | Coupling agents between mineral fillers and polymers | Plüss-Staufer AG (CH) | 1985-09-18 | — | — | EP | disclosed |
| WO-1985003505-A2 | COUPLING AGENT BETWEEN MINERAL FILLERS AND POLYMERS | PLÜSS-STAUFER AG (CH) | 1985-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | CYP3A4 838/4885ALDH1A1 1514/4885POLB 1735/4885 |
| US-20050197368-A1 | Novel compounds as inhibitors of cell proliferation and viral infections | MKI67, CDK7, CD4 | CYP3A4 3286/4885ALDH1A1 4079/4885POLB 1814/4885 |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | CLIC1, PKD2, PKD1 | CYP3A4 3308/4885ALDH1A1 2904/4885POLB 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.